Jeffrey Dome: Promising Activity of Paclitaxel-based Treatment Regimens for Relapsed Wilms tumor
Jeffrey Dome, Senior Vice President at Center for Cancer and Blood Disorders, Children’s National Hospital, shared a post by Children’s National Hospital, on LinkedIn, adding:
“We are excited to share these results that show promising activity of paclitaxel-based treatment regimens for relapsed Wilms tumor. Further research is needed, though these findings provide an additional treatment option for pediatric oncologists caring for patients with Wilms tumor that has returned after standard therapies.”
Quoting Children’s National Hospital‘s post:
“This new study shows promising results for paclitaxel-containing regimens in children with recurrent Wilms tumor. Among patients with measurable disease, 42.3% had a partial response and 15.3% had stable disease—for a clinical benefit rate of 57.6%.
“These findings provide an additional treatment option for pediatric oncologists caring for patients with recurrent Wilms tumor and merit prospective evaluations of paclitaxel-based regimens,” says Dr. Jeffrey Dome, corresponding author.”
Title: Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms Tumor
Authors: Alissa Groisser, Amy Frantz, James I. Geller, Michael V. Ortiz, David Walterhouse, Mark Ranalli, Wendy Woods-Swafford, Peter Schoettler, Timothy Garrington, Elizabeth A. Mullen, Shifra Ash, Pooja Bardhan, Frank Balis, Jeffrey S. Dome
Read More about Wilms Tumor on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023